Skip to main content

Table 2 Demographic and clinical characteristics

From: Association between warfarin and COVID-19-related outcomes compared with direct oral anticoagulants: population-based cohort study

 

Current use of direct oral anticoagulant

Current use of warfarin

Total

280,407

92,339

Age as of 1 Mar 2020

  

18– < 40

510 (0.2)

112 (0.1)

40– < 50

2320 (0.8)

361 (0.4)

50– < 60

12,788 (4.6)

2245 (2.4)

60– < 70

42,407 (15.1)

9824 (10.6)

70– < 80

98,848 (35.3)

34,051 (36.9)

80+

123,534 (44.1)

45,746 (49.5)

Median, IQR

78 (71–84)

79 (73–85)

Sex

  

Female

122,778 (43.8)

36,414 (39.4)

Body mass index

  

 < 18.5

5437 (1.9)

1199 (1.3)

18.5–24.9

72,658 (25.9)

21,998 (23.8)

25–29.9

94,621 (33.7)

31,981 (34.6)

30–34.9

57,590 (20.5)

19,592 (21.2)

35–39.9

24,032 (8.6)

8114 (8.8)

40+

12,586 (4.5)

4539 (4.9)

Missing

13,483 (4.8)

4916 (5.3)

Ethnicity

  

White

201,046 (71.7)

66,800 (72.3)

Mixed

548 (0.2)

115 (0.1)

Asian/Asian British

3911 (1.4)

766 (0.8)

Black

1289 (0.5)

258 (0.3)

Other

1100 (0.4)

281 (0.3)

Missing

72,513 (25.9)

24,119 (26.1)

Index of multiple deprivation

  

1 (least deprived)

57,570 (20.5)

17,703 (19.2)

2

56,881 (20.3)

18,400 (19.9)

3

55,654 (19.8)

19,056 (20.6)

4

54,758 (19.5)

18,615 (20.2)

5 (most deprived)

55,544 (19.8)

18,565 (20.1)

Smoking status

  

Never

101,492 (36.2)

33,005 (35.7)

Former

161,752 (57.7)

54,463 (59.0)

Current

16,828 (6.0)

4834 (5.2)

Missing

335 (0.1)

37 (0.0)

Hazardous alcohol use

28,375 (10.1)

7819 (8.5)

Care home residence

8133 (2.9)

1039 (1.1)

Comorbidities

  

Hypertension

195,078 (69.6)

66,888 (72.4)

Heart failure

71,427 (25.5)

26,926 (29.2)

Myocardial infarction

31,911 (11.4)

10,414 (11.3)

Peripheral arterial disease

14,273 (5.1)

5091 (5.5)

Stroke/transient ischaemic attack

60,271 (21.5)

18,470 (20.0)

Venous thromboembolism

19,927 (7.1)

8202 (8.9)

Diabetes

  

Controlled (HbA1c < 58 mmols/mol)

61,178 (21.8)

23,893 (25.9)

Uncontrolled (HbA1c ≥ 58 mmols/mol)

22,672 (8.1)

7696 (8.3)

HbA1c not measured

838 (0.3)

298 (0.3)

COPD

36,189 (12.9)

11,272 (12.2)

Other respiratory diseases

16,444 (5.9)

4731 (5.1)

Cancer

49,488 (17.6)

16,240 (17.6)

Immunosuppression

1688 (0.6)

528 (0.6)

Chronic kidney disease

95,715 (34.1)

34,633 (37.5)

Primary care consultations

Median, IQR

10 (6–17)

16 (9–27)

Min, Max

0, 432

0, 307

A&E attendance

  

Median, IQR

0 (0–1)

0 (0–1)

Min, Max

0, 69

0, 45

Flu vaccination

220,153 (78.5)

78,558 (85.1)

Medications

  

Oestrogen/oestrogen-like drugs

1652 (0.6)

361 (0.4)

Antiplatelets

19,030 (6.8)

4108 (4.4)

  1. COPD, Chronic obstructive pulmonary disease